Alterity Therapeutics Limited Overview
Alterity is a single-asset, late-clinical-stage neurology biotech built on the "metal hypothesis" of neurodegeneration that its predecessor Prana Biotechnology pioneered. Its lead candidate, ATH434, is an oral, brain-penetrant small molecule designed as an iron chaperone that redistributes excess labile iron and inhibits alpha-synuclein aggregation. In 2025, ATH434 produced positive results in a randomised, double-blind, placebo-controlled Phase 2 trial in Multiple System Atrophy (MSA) — a rare, rapidly fatal Parkinsonian disorder with no approved disease-modifying therapy — and in an open-label study in advanced MSA. In June 2026 the FDA End-of-Phase 2 meeting aligned on a single ~200-patient pivotal Phase 3 using modified UMSARS Part I, which together with confirmatory evidence could support approval. With A$37.3M cash at 30 June 2026, Fast Track and Orphan designations, and new composition-of-matter protection to 2045, Alterity is positioned as one of the more advanced disease-modifying MSA programs globally, but remains pre-revenue and capital-dependent.
Company's own description. Alterity describes itself as a clinical-stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases, focused on disease-modifying therapies for MSA and related Parkinsonian disorders and preparing to initiate a Phase 3 pivotal trial in MSA; it also cites a broad drug discovery platform generating patentable chemical compounds (FY2026 20-F filing release, 31 Aug 2026; EGM release 29 May 2026).
Independent characterisation. Alterity is a pre-revenue drug developer whose economic value rests almost entirely on ATH434 in MSA. Its "revenue" is bank interest — A$1,716,656 in FY2026, up 284.7% on higher cash balances (FY2026 Appendix 4E). Non-dilutive funding comes from the Australian R&D Tax Incentive (A$3.6M recognised in FY2026; A$3.98M refund received July 2026). The business model is classic biotech: fund development through equity (A$40M Feb 2025 and A$20M Sep 2025 placements), then either partner/license ATH434 or commercialise in an orphan market. Management has been engaged in discussions with multiple pharmaceutical companies about strategic collaborations (Q3 FY2026 4C).
Strategy
Strategic themes (FY2026 Chairman's letter and releases): (1) initiate the Phase 3 trial of ATH434 in MSA — the "central operational objective for FY2027", with trial activities by end of CY2026; (2) manage capital carefully and preserve strategic options; (3) evaluate partnering, licensing and other strategic opportunities alongside funding options; (4) broaden institutional engagement in Australia and the US (rationale for the 1:50 consolidation); (5) extend ATH434 into larger indications such as Parkinson's disease, supported by the 2045 patent.
Guidance: No financial guidance; operational guidance is Phase 3 initiation by end of CY2026.
Product Portfolio
| Asset | Description & capabilities | Indication / target | Status (Oct 2026) | Regulatory designations | Pricing |
|---|---|---|---|---|---|
ATH434 (oral; mesylate salt) | Small-molecule iron chaperone; designed to reduce labile iron accumulation and inhibit alpha-synuclein aggregation; brain-penetrant | Multiple System Atrophy | Phase 3-ready; FDA-aligned pivotal design (~200 patients, modified UMSARS Part I primary endpoint, 50 mg twice daily); trial activities targeted to begin by end of CY2026; first registrational GMP batch produced | US Fast Track; US and EU Orphan Drug | Not disclosed; company presentation cited ~US$2.4B peak sales potential (H2 2025 presentation, via Quartr) |
ATH434 | Same molecule | Parkinson's disease and other neurodegenerative disorders | Preclinical/strategic option; new patent cited as supporting broader investment | — | — |
ATH434-201 (completed) | Randomised, double-blind, placebo-controlled Phase 2, 52 weeks; 50 mg cohort ~46% relative treatment effect on UMSARS Part I at week 52; MuSyCA analysis 41% relative effect | Early MSA | Completed; positive topline Jan 2025 | — | — |
ATH434-202 (completed) | Open-label Phase 2 in advanced MSA (safety, efficacy, target engagement) | Advanced MSA | Positive data 2025 | — | — |
bioMUSE | Natural history / biomarker study with Vanderbilt University Medical Center; neuroimaging published | MSA | Supports endpoint/biomarker strategy | — | — |
Discovery platform | Library of novel compounds from metal-protein attenuation chemistry (legacy of PBT program) | Major neurodegenerative indications | Research | — | — |
PBT2 (legacy) | Earlier-generation compound; later explored as antimicrobial | Legacy | Non-core | — | — |
Financial Narrative
Primary sources: Appendix 4E reports FY2022–FY2026 (ASX/SEC 6-K), FY2026 Form 20-F, H1 FY2026 6-K, quarterly 4Cs.
Income statement (A$ M):
FY2021 comparison: revenue A$20,676; net loss A$15,309,353 (FY2022 Appendix 4E). Five-year revenue CAGR is not meaningful (interest only). EBITDA ≈ operating loss (depreciation immaterial; not separately verified).
Half-year detail H1 FY2026 (6 months to 31 Dec 2025, A$ M): revenue 0.91; R&D tax incentive 2.80; R&D expense 7.84; G&A 5.12 (incl. 2.22 share-based payments); net loss 9.62 (+34% YoY) (H1 FY2026 6-K via Stock Titan).
Balance sheet (A$ M):
Notes: FY2026 NTA per share (19.56c) is post 1:50 consolidation; FY2025 comparative restated to 22.94c on the same basis. Implied FY2026 net tangible assets ≈ A$42.5M (19.56c × 217.5M shares — derived). Total equity at 31 Dec 2025 was A$54.27M (H1 FY2026). No borrowings are disclosed; net debt is negative (net cash = cash).
Cash flow (A$ M):
FY2026 quarterly operating outflows: Q2 A$5.28M; Q4 A$7.17M (quarterly 4Cs). FY2026 investing flows immaterial (Q3 4C).
Ratios. ROE (FY2026, net loss / implied closing NTA ≈ A$42.5M) ≈ −55% (derived); ROA, ROIC, interest coverage, asset turnover, net debt/EBITDA and cash conversion cycle are not meaningful. Debt/equity: 0.
Commentary. The loss profile tracks clinical intensity. FY2024's A$19.1M loss reflected running two Phase 2 trials; FY2025 fell to A$12.1M as trials completed and tax incentives/interest offset spend; FY2026 nearly doubled to A$23.4M as Phase 3 preparation (CMC scale-up, GMP registrational batch, regulatory work) and G&A (including share-based payments after board changes) increased. Cash nonetheless rose from A$12.6M (FY2024) to A$37.3M (FY2026) because of A$60M of placements in 2025. On FY2026 operating burn of ~A$22.5M, the year-end cash plus the A$3.98M July refund implies roughly 18–20 months of runway at current spend — but a ~200-patient global Phase 3 will raise burn substantially, so the company is not funded through Phase 3 readout without partnering or new equity.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Domicile | Ownership | Role |
|---|---|---|---|
Alterity Therapeutics Limited | Australia | Parent (listed) | Holding, R&D sponsor, IP owner |
Alterity Therapeutics Inc. | United States | 100% | US operations / clinical-regulatory presence |
Alterity Therapeutics UK Limited | United Kingdom | 100% | UK/European activities |
Revenue by Segment
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Neurodegenerative drug development — revenue (AUD Mn) | 0.27 | 0.45 | 1.72 |
Neurodegenerative drug development — net loss (AUD Mn) | -19.12 | -12.15 | -23.40 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue — interest income (AUD Mn) | 0.003 | 0.016 | 0.27 | 0.45 | 1.72 |
Gross profit (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Loss before income tax (AUD Mn) | — | -13.70 | -19.08 | — | — |
Net loss after tax (AUD Mn) | -12.85 | -13.81 | -19.12 | -12.15 | -23.40 |
R&D tax incentive other income (AUD Mn) | — | — | — | — | 3.6 |
YoY change in net loss (%) | -16.1 | 7.5 | 38.5 | -36.5 | 92.6 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents (AUD Mn) | — | 15.77 | 12.64 | 33.16 | 37.32 |
Net assets / total equity (AUD Mn) | — | 22.81 | 13.80 | — | — |
Net tangible assets per share (A$ cents, as reported) | 1.48 | 0.94 | 0.27 | 0.46 | 19.56 |
Total debt (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Goodwill & intangibles (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | — | — | — | -11.5 | -22.52 |
Capex (AUD Mn) | — | — | — | — | 0 |
Free cash flow (AUD Mn) | — | — | — | -11.5 | -22.52 |
Financing cash flow (AUD Mn) | — | — | — | — | 19.13 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Key Financials
| Metric | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 |
|---|---|---|---|
Cash at quarter end (AUD Mn) | 49.20 | 44.53 | 37.32 |
Region revenue (AUD Mn)
| Region revenue (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia — interest income (AUD Mn, total group) | 0.27 | 0.45 | 1.72 |
Americas (AUD Mn) | 0 | 0 | 0 |
EMEA (AUD Mn) | 0 | 0 | 0 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
ASX price 30 Jul 2026 | A$0.505 (post-consolidation) | InvestSMART |
Pre-consolidation price at Sep 2025 placement | A$0.013 (≈A$0.65 consolidated-equivalent) | InvestSMART |
Pre-consolidation price 21 Nov 2025 | A$0.009 (≈A$0.45 equivalent) | InvestSMART |
Market cap (derived) | ≈A$110M | 20-F share count × price |
Enterprise value (derived) | ≈A$73M (market cap less A$37.3M cash) | Derived |
P/B (derived) | ≈2.6x (A$110M / ≈A$42.5M NTA) | Derived |
Analyst coverage | Additional independent research coverage attracted in FY2026 (names/targets not disclosed in sources reviewed) | FY2026 Chairman's letter |
Dividends | Never paid; none expected | 20-F |
Credit ratings | Not rated; no debt | — |
Equity raised (AUD Mn) | FY2022 | FY2023 |
Analyst Conclusions
Management guidance: Initiate ATH434 Phase 3 trial activities in MSA by end of CY2026; continue evaluating partnering, licensing and funding alternatives. No consensus revenue/earnings expectations (pre-revenue).
Bull case
-
The pivotal trial is built around the endpoint on which ATH434 already showed a ~46% relative effect (50 mg, week 52), and the FDA has agreed a single trial plus confirmatory evidence could suffice.
-
Scarcity value: an oral, Phase 3-ready disease-modifying MSA asset with orphan/Fast Track status and IP to 2045 is attractive to pharma — a licence could fund Phase 3 and re-rate the ~A$73M enterprise value.
-
Balance sheet (A$37.3M cash + A$3.98M refund, no debt) funds start-up activities without immediate dilution.
Bear case
-
Single-asset binary risk: MSA trials have failed in Phase 3 before, and Phase 2 effect sizes in small trials frequently shrink.
-
A global ~200-patient trial will likely require tens of millions more than current cash; absent a partner, further dilutive raises are near-certain (burn already doubled to A$23.4M).
-
Better-funded competitors (Lundbeck, Teva) could reach the market first or set a higher efficacy bar.
Catalysts / monitorables (next 12 months): Phase 3 initiation (first site activation/first patient); partnering announcement; financing (placement/ATM/licence); FY2027 quarterly burn; additional ex-US regulatory interactions (EMA); publications of Phase 2 data; competitor MSA readouts; Nasdaq compliance after consolidation; inclusion in indices.
Analyst verdict. Alterity has, after nearly three decades, converted the metal-chaperone thesis that Prana pioneered into a genuinely late-stage asset. The 2025 Phase 2 data and the 2026 regulatory sequence — Type C feedback on pharmacology, nonclinical and CMC, then an End-of-Phase 2 meeting aligning on a single pivotal trial — represent the most de-risked position in the company's history. The design agreed with the FDA (about 200 patients, modified UMSARS Part I, 50 mg twice daily) is efficient by neurology standards, and the choice of an endpoint already showing a clinically meaningful effect in Phase 2 is a material advantage. Patent protection to 2045 and orphan exclusivity provide a long commercial runway if successful.
The constraints are capital and concentration. FY2026's A$23.4M loss shows spending has stepped up before the trial has even started; Phase 3 will lift it further. Cash of A$37.3M is adequate for start-up and early enrolment, not for completion. Management's repeated references to pharma discussions suggest a partnership is the preferred route, and the regulatory clarity obtained in mid-2026 is precisely the de-risking event licensors typically wait for. Absent a deal, investors should expect another sizeable raise within roughly 12–18 months.
The next 12 months should be judged on execution (trial initiation on time) and on the quality of funding — a partnership that preserves meaningful economics would be the strongest validation; a deeply discounted equity raise would signal the market's scepticism.
Sources consulted: FY2026 Appendix 4E, Chairman's letter and Form 20-F (via Webull bulletin, 28 Aug 2026); 20-F filing release (31 Aug 2026); Appendix 4E FY2022–FY2025 (ASX; SEC 6-K exhibits); H1 FY2026 6-K (Stock Titan); Q2, Q3, Q4 FY2026 Appendix 4C summaries (InvestSMART, GlobeNewswire/iTiger, Quartr, Midas); Placement releases 10 Feb 2025 and 8 Sep 2025 (ASX, SEC, BioSpace, Biotech Dispatch); Board-change 6-K 21 Nov 2025 (SEC; Stockhead; InvestSMART); Patent release 12 Aug 2026 (InvestSMART); EGM results 29 May 2026; FY2022/FY2024/FY2025 Form 20-F (SEC); Panabee; TheOfficialBoard; Quantisnow.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Since | Background / notes | Source |
|---|---|---|---|---|
Julian Babarczy | Non-Executive Chair | 21 Nov 2025 | 25+ years in finance and investment/funds management; director/chair of several ASX companies | 6-K 21 Nov 2025; Stockhead |
David Stamler, M.D. | Managing Director & CEO | CEO Jan 2021; MD 21 Nov 2025 | Joined May 2017 as CMO/SVP Clinical Development | FY2022 20-F; 6-K Nov 2025 |
Peter Marks | Non-Executive Director | — | Directorships incl. Noxopharm, Iris Metals, EverGreen Lithium; previously Elsight, Nyrada | FY2025 20-F |
Ann Cunningham | Independent Non-Executive Director | Apr 2026 | — | Q4 FY2026 4C |
Abby Macnish Niven | CFO & Company Secretary | CFO 30 Sep 2024; Co Sec 18 Nov 2024 | — | FY2025 20-F |
Daniel O. Claassen, M.D. | Chief Medical Advisor | Mar 2026 | — | Q3 FY2026 4C |
Competitive Landscape
Key Competitors
| Company | Asset / approach | Positioning vs Alterity |
|---|---|---|
H. Lundbeck A/S | Amlenetug (anti-alpha-synuclein antibody) | Large-cap sponsor; late-stage MSA program — most direct well-funded rival |
Teva Pharmaceutical | Emrusolmin (oligomer modulator, licensed from MODAG) | Big-pharma backed MSA program |
Theravance Biopharma | Ampreloxetine (symptomatic, neurogenic orthostatic hypotension in MSA) | Symptomatic, potentially complementary |
Ionis / Biogen | Antisense against alpha-synuclein (MSA) | Genetic-medicine approach, intrathecal |
Corestem (Korea) | Mesenchymal stem cell therapy for MSA | Regional cell therapy |
AC Immune | Alpha-synuclein immunotherapies | Earlier-stage synucleinopathy |
Vaxxinity | UB-312 anti-alpha-synuclein vaccine | Early clinical |
Inhibikase Therapeutics | Kinase inhibitor programs in synucleinopathies | Small-cap peer |
Biohaven | Verdiperstat (failed MSA Phase 3, 2021) | Illustrates late-stage risk |
Annovis Bio | Translational inhibitors in neurodegeneration | Adjacent small-cap |
Peer Comparison FY2026
| Metric | Alterity | Lundbeck | Teva | Theravance |
|---|---|---|---|---|
Revenue | Nil (interest A$1.7M FY2026) | Multi-billion DKK | Multi-billion US$ | Commercial royalties/product revenue |
MSA stage | Phase 3-ready, oral, disease-modifying | Late-stage antibody | Clinical small molecule | Phase 3 symptomatic |
Route | Oral | IV infusion | Oral | Oral |
R&D intensity | ~100% of spend | Moderate | Low-moderate | High |
Recent Developments
--



